What are the contraindications for using avatrombopag tablets?

Avatrombopag (Avatrombopag) is an oral thrombopoietin receptor agonist. It is mainly used to treat patients with chronic liver disease who require invasive procedures due to thrombocytopenia to increase platelet counts and reduce the need for platelet transfusions. The drug stimulates the thrombopoietin receptor to promote the proliferation and differentiation of megakaryocytes in the bone marrow, thereby increasing the number of platelets. Although avatrombopag has good clinical efficacy and safety, there are still certain taboos and precautions during use. Understanding and complying with these taboos is crucial to ensure patient safety and improve treatment effects.

Avatrombopag is contraindicated in patients allergic to its components. Allergy to drug ingredients may lead to severe allergic reactions, such as rash, difficulty breathing, facial swelling, etc., which may even be life-threatening. Therefore, patients should inform their doctors in detail whether they have any related allergies before use, including allergic reactions to avatrombopag or similar thrombopoietin receptor agonists, to avoid adverse events caused by the use of this drug. In addition, patients who are allergic to any excipients in the drug should also use it with caution.

Avatrombopag is contraindicated in patients with active thrombosis or a high risk of thrombosis. Because this drug can significantly increase platelet counts, it may cause a hypercoagulable state, increasing the risk of thrombotic events. Patients with deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke, or other thrombotic disorders should avoid the use of avatrombopag or use it with caution and under strict supervision. In addition, patients with obvious thrombophilia and active thrombosis should also weigh the pros and cons and carefully decide whether to use this drug to prevent serious thrombotic complications.

Pregnant and nursing women should avoid the use of avatrombopag. There is currently insufficient clinical data to prove the safety of avatrombopag in pregnant women. Although animal studies have shown certain risks, women who are pregnant or planning to become pregnant should avoid taking this drug unless their doctor clearly assesses that the benefits outweigh the risks and cannot be replaced. For lactating women, it is not clear whether the drug is secreted through breast milk. To ensure the safety of newborns, it is recommended to use avatrombopag with caution during breastfeeding.

Avatrombopag should also be used with caution in patients with severe hepatic impairment. Although avatrombopag is commonly used in patients with chronic liver disease, in patients with very severe hepatic impairment, drug metabolism may be affected, resulting in elevated drug concentrations in the body, thereby increasing the risk of adverse reactions. Such patients should be carefully evaluated before use, and the dose should be adjusted or other alternative treatment options adopted if necessary.

In summary, when using avatrombopag, special attention should be paid to avoid use by allergic patients, patients with active thrombosis, pregnant women and lactating women, and it should be used with caution in patients with severe hepatic insufficiency. Patients should truthfully inform their doctors about their medical history and related conditions before taking medication. Doctors should comprehensively evaluate the patient's condition to ensure the safety and effectiveness of medication use. At the same time, during the medication period, patients should closely observe their own reactions and seek medical attention promptly if abnormal symptoms occur to avoid serious adverse events. Complying with these taboos and precautions can maximize patient safety and maximize the therapeutic value of avatrombopag.

Reference materials:https://go.drugbank.com/drugs/DB11995